Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CHC Healthcare GroupTPE:4164 +1.34%79 EV-to-EBITDA is 8.42 as of Aug. 26, 2026, which is 23% below its 10-year median of 10.88. GuruFocus rates TPE:4164 with a GF Score™ of 79/100 and a GF Value™ of NT$49.03 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 99 Medical Distribution companies, CHC Healthcare Group ranks better than 52.53% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, CHC Healthcare Group's enterprise value is NT$9,803 Mil.
CHC Healthcare Group's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$1,164 Mil. Therefore, CHC Healthcare Group's EV-to-EBITDA for today is 8.42.
The historical rank and industry rank for CHC Healthcare Group's EV-to-EBITDA or its related term are showing as below:
TPE:4164'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.45 Med: 10.88 Max: 18.72
Current: 8.43
During the past 13 years, the highest EV-to-EBITDA of CHC Healthcare Group was 18.72. The lowest was 6.45. And the median was 10.88.
TPE:4164's EV-to-EBITDA is ranked better than 52.53% of 99
companies
in the Medical Distribution industry
Industry Median: 8.59
vs TPE:4164: 8.43
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
CHC Healthcare Group (TPE:4164) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CHC Healthcare Group's PE Ratio (TTM) for today is calculated as:
CHC Healthcare Group's share price for today is NT$26.55.
CHC Healthcare Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.140.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for CHC Healthcare Group's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4164 vs MCK, COR, CAH: EV-to-EBITDA Comparison
For the Medical Distribution subindustry, CHC Healthcare Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CHC Healthcare Group EV-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, CHC Healthcare Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where CHC Healthcare Group's EV-to-EBITDA falls into.
CHC Healthcare Group's current Enterprise Value is NT$9,803 Mil.
CHC Healthcare Group's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1,164 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHC Healthcare Group (TPE:4164) has a EV-to-EBITDA of 8.42 as of Aug. 26, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on CHC Healthcare Group. This is 23% below median its historical median of 10.88. Over the past decade, CHC Healthcare Group's EV-to-EBITDA has ranged from 6.45 to 18.72. According to the industry distribution chart, CHC Healthcare Group ranks #47 out of 99 companies in the Medical Distribution industry, placing it in the top 47.5%.
Is CHC Healthcare Group's EV-to-EBITDA too high?
CHC Healthcare Group's current EV-to-EBITDA of 8.42 is 23% below median its 10-year median of 10.88. Over the past 10 years, this metric has ranged from a low of 6.45 to a high of 18.72. The Medical Distribution industry median EV-to-EBITDA is 8.59. CHC Healthcare Group's value of 8.42 is 2% below this industry median. Based on the distribution chart, CHC Healthcare Group ranks #47 out of 99 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, CHC Healthcare Group has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does CHC Healthcare Group's EV-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, CHC Healthcare Group ranks #47 out of 99 companies for EV-to-EBITDA. This puts CHC Healthcare Group in the upper half of its industry. The industry median EV-to-EBITDA is 8.59. CHC Healthcare Group's value of 8.42 is 2% below this benchmark. Historically, CHC Healthcare Group's own EV-to-EBITDA has ranged from 6.45 to 18.72 over the past decade. While the company's 10-year median is 10.88 vs. the industry median of 8.59, CHC Healthcare Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Distribution company?
The median EV-to-EBITDA among Medical Distribution companies is 8.59, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CHC Healthcare Group's current EV-to-EBITDA of 8.42 is 2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on CHC Healthcare Group. For the Medical Distribution industry, the median EV-to-EBITDA is 8.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CHC Healthcare Group's current EV-to-EBITDA is 8.42, which is 23% below median its own 10-year median of 10.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CHC Healthcare Group stock overvalued right now?
Based on GuruFocus' analysis, CHC Healthcare Group (TPE:4164) is currently considered Possible Value Trap. The stock's GF Value™ is NT$49.03, compared to a current price of NT$26.55 — trading 45.8% below its estimated fair value. The current EV-to-EBITDA is 8.42, which is 23% below median its 10-year median of 10.88 and 2% below the Medical Distribution industry median of 8.59. CHC Healthcare Group's overall GF Score™ is 79/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For CHC Healthcare Group (TPE:4164), the current EV-to-EBITDA is 8.42 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CHC Healthcare Group (TPE:4164) Overvalued in 2026?
Based on GuruFocus' analysis, CHC Healthcare Group stock appears to be undervalued.
The current stock price of NT$26.55 is trading 45.8% below its estimated GF Value™ of NT$49.03.
GuruFocus considers CHC Healthcare Group to be Possible Value Trap.
Key valuation signals for TPE:4164:
EV-to-EBITDA: 8.42 (23% below median its 10-year median of 10.88)
GF Value™: NT$49.03 vs. price of NT$26.55 (45.8% below fair value)
Industry Position: 2% below the Medical Distribution median (#47 of 99)
No single metric tells the full story. See the TPE:4164 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CHC Healthcare Group is a Taiwan-based company engaged in the trading of pharmaceutical products and health food, as well as the sale, leasing, installation, and repair of medical instruments. It is engaged in the distribution of radiotherapy equipment, including equipment used in radiation oncology, ophthalmology, dentistry, and neuroscience. It also provides medical equipment consulting for hospitals and clinics. It earns revenues from the sale of drugs, the sale of medical instruments, repairs, maintenance, and other services.
79GF Score
Get the complete analysis for TPE:4164
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4164 has been successfully added to your 
